News

According to the FDA, Fast Track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical

The companies have signed a letter of intent to enter into collaboration for the development of a novel coronavirus vaccine by using their technologies. GSK CEO Emma Walmsley

In this regard, Hope Biosciences will be evaluating the safety and efficacy of its adipose-derived mesenchymal stem cells (HB-adMSCs) in the mid-stage clinical trial. The phase 2 trial,

“We are thankful to the amazing team at MHRA for the careful and expeditious consideration that led to clearance of our application,” said Dr. Wayne Holman, Co-Founder of Ridgeback

ASC09 has an unprecedented high genetic barrier to resistance and has completed Phase I and Phase IIa clinical trials, which have shown potent anti-viral activity. Previous clinical trials

As part of the deal, Alnylam will secure up to $2bn from Blackstone for the advancement of its RNAi medicines, which are believed to have the potential to

The pharma company has signed an agreement with the US National Institute of Allergy and Infectious Diseases (NIAID) to investigate baricitinib as an arm in the latter’s Adaptive

ARO-ENaC utilizes Arrowhead’s proprietary Targeted RNAi Molecule (TRiM) platform and is the company’s first inhaled RNAi candidate to target pulmonary epithelium. Chris Anzalone, Ph.D., president and chief executive

“We are excited to advance EC-18 as a potent drug candidate against COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus, to improve patient health,” said Ki Young Sohn,